Suppression of Experimental Autoimmune Uveitis by Angiotensin II Type 1 Receptor Blocker Telmisartan
Authors:
Open Access
- 1 May 2009
- journal article
- research article
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 50 (5) , 2255-2261
Abstract
Purpose. Angiotensin II type 1 receptor (AT1-R) blockers are used widely for the treatment of patients with hypertension. Recent reports have suggested that AT1-R also plays a key role in various inflammatory conditions. The aim of this study was to examine whether blockade of AT1-R is effective in the suppression of murine experimental autoimmune uveoretinitis (EAU). methods. C57BL/6 mice were immunized with human interphotoreceptor retinoid binding protein–derived peptide 1–20 (hIRBP-p). Telmisartan, an AT1-R blocker, was administrated daily by intraperitoneal injection. On day 21 after immunization, the severity of EAU was assessed clinically and histopathologically. With the use of flow cytometry, the activation of draining lymph node (LN) cells was assessed by cell proliferation response against hIRBP-p and by the number of CD44high activated CD4+ T cells present. In addition, mRNA expression of ICAM-1, MCP-1, and IFN-γ in the eye was analyzed by reverse-transcriptase PCR, and the number of retinal adherent leukocytes was counted by retinal perfusion labeling. results. Telmisartan significantly suppressed EAU clinically and histopathologically. Intraocular mRNA expression of ICAM-1 and MCP-1 was downregulated, and the retinal adherent leukocyte counts were significantly decreased in telmisartan-treated mice compared with vehicle-treated mice. LN cell proliferative responses against hIRBP-p and the number of CD44highCD4+ T cells were remarkably reduced in telmisartan-treated mice. conclusions. Systemic administration of telmisartan significantly suppressed EAU by the inhibition of antigen-specific T-cell activation in the LNs and of leukocyte adhesion in the retina. These results indicate that telmisartan may be a novel therapeutic regimen for patients with endogenous uveitis.Keywords
This publication has 25 references indexed in Scilit:
- Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in ratsGraefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Infliximab Treatment for Ocular and Extraocular Manifestations of Behçet's DiseaseJapanese Journal of Ophthalmology, 2007
- Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: Selenium binding protein is a novel autoantigen in Behcet's diseaseExperimental Eye Research, 2007
- Epidemiological Survey of Intraocular Inflammation in JapanJapanese Journal of Ophthalmology, 2007
- The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitisEuropean Journal of Immunology, 2006
- Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activationDiabetologia, 2006
- Current Concepts in the Etiology and Treatment of Behçet DiseaseSurvey of Ophthalmology, 2005
- Angiotensin receptor blockers suppress antigen‐specific T cell responses and ameliorate collagen‐induced arthritis in miceArthritis & Rheumatism, 2005
- Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cellsJournal of Neuroimmunology, 2004
- Chemokine and chemokine receptor expression during experimental autoimmune uveoretinitis in miceGraefe's Archive for Clinical and Experimental Ophthalmology, 2003